Evidence review

MOTS-c Human Studies: What the Evidence Actually Shows

MOTS-c has a strong, mechanistic story and real human measurements behind it, but the efficacy data is still largely preclinical. Here is the honest split between what is shown in mice and what is confirmed in people.

  • Mouse metabolism

    Convincing

  • Human observational

    Levels, exercise, age

  • Human efficacy trial

    None completed

  • Mechanism

    Well mapped

Start here

Strong in the lab, early in the clinic

MOTS-c is a mitochondrial-derived peptide studied for metabolism and insulin sensitivity, with its mechanism mapped well enough to explain the interest.

The core point: the gap here is not mechanism, it is human efficacy. The mouse data and the mechanism are consistent, and people have been measured observationally, but no completed human efficacy or dose-finding trial yet confirms what MOTS-c does when given to a person.

The evidence, by tier

What has been studied, and how strong it is

Strongest in mouse metabolism, real but observational in humans, with the efficacy trial still the gap.

  • Mouse, metabolism

    AMPK and insulin sensitivity

    The seminal study showed MOTS-c injections activated AMPK in skeletal muscle and improved whole-body insulin sensitivity, including on a high-fat diet. The mechanistic backbone for everything that follows.

    Lee et al., Cell Metabolism 2015 (PMID 25738459)

  • Mouse and human

    Exercise-induced, declines with age

    MOTS-c rose with exercise and was tied to age-related physical decline and muscle homeostasis, using both mouse models and human samples. Strong supporting evidence, though not a treatment trial.

    Reynolds et al., Nature Communications 2021 (PMID 33473109)

  • Human, observational

    Levels tracked in people

    Human studies have measured circulating MOTS-c and found it declines with age and responds to metabolic state. This is real human data, but it describes the molecule's biology rather than testing it as a supplement.

  • The gap

    Completed human efficacy or dose trial

    No completed, peer-reviewed human dose-ranging or efficacy trial exists. A Phase 2a study was ongoing as of 2026, so effects and dosing in people remain open questions.

The honest read

Promising biology, unproven as a protocol

MOTS-c is one of the more mechanistically interesting compounds in the longevity and metabolic space, and the mouse work is consistent rather than a one-off. That is a legitimate reason for research interest. It is not the same as evidence that injecting it produces a specific benefit in a healthy person.

The dosing conventions circulating online are not derived from a completed human trial, so they should be treated as unvalidated. Until the human efficacy data arrives, the sober position is that MOTS-c is a promising research molecule whose effects in people are extrapolated, not demonstrated.

Legal status

Where MOTS-c stands in the US

A draft compounding pathway, but not an approved drug.

MOTS-c is not FDA-approved. The FDA panel voted in its favor in July 2026, and the October 2026 draft HHS policy would let 503A pharmacies compound MOTS-c acetate by injection, by prescription. That is a draft and nonbinding. Research-grade MOTS-c is sold for laboratory use only, not for human consumption. Full picture on the MOTS-c profile.

Frequently asked questions

Has MOTS-c been tested in humans?

Human work so far is mostly observational rather than controlled efficacy trials. Studies have measured circulating MOTS-c in people, finding that levels decline with age and respond to exercise, and a 2021 study tied it to age-related physical decline using both mouse and human samples. There is no completed, peer-reviewed human dose-ranging trial, though a Phase 2a study was ongoing as of 2026.

What is the strongest evidence for MOTS-c?

The strongest efficacy data is still preclinical. A 2015 mouse study showed MOTS-c injections activated AMPK in skeletal muscle and improved whole-body insulin sensitivity, including on a high-fat diet. That study is the mechanistic backbone, and the human observational work is consistent with it, but mouse metabolic results do not automatically transfer to people.

How does MOTS-c work?

MOTS-c is a mitochondrial-derived peptide, encoded in mitochondrial DNA rather than nuclear DNA. Under metabolic stress it is proposed to move to the nucleus and, downstream, activate AMPK, the cell's main energy sensor, mainly in skeletal muscle. Because muscle handles most insulin-stimulated glucose disposal, that is the proposed basis for its effects on glucose, fat oxidation and insulin sensitivity.

Is MOTS-c linked to aging?

Circulating MOTS-c levels have been reported to decline with age in human studies, and the 2021 exercise study reinforced a link to age-related physical decline and muscle homeostasis. That is why it is discussed as a candidate mitochondrial peptide of aging, but this framing is an active research hypothesis, not an established clinical fact.

Is MOTS-c FDA-approved?

No. MOTS-c is not FDA-approved for any indication. The July 2026 FDA advisory committee voted in favor of adding it to the 503A compounding list, and the October 2026 HHS draft policy would let 503A pharmacies compound MOTS-c acetate by injection, by prescription. That is a draft and nonbinding. Research-grade MOTS-c is sold for laboratory use only, not for human consumption.

Should the mouse data change what I expect?

Treat it as a reason for interest, not proof. The metabolic effects in mice are consistent and mechanistically plausible, but the compound has no completed human efficacy or dose-finding trial. Until those exist, claims about what MOTS-c does in people are extrapolated from animal data and human observational measurements.

Track your protocol with the evidence in view

Log doses, glucose, insulin markers and training in one place, and watch what actually moves. Free.

Sources

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. PMID 25738459
  2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. PMID 33473109

This content is for informational purposes only and is not medical advice. MOTS-c is not FDA-approved in the United States. No completed human efficacy or dose-finding trial has been published; the strongest data is preclinical. Research-grade MOTS-c is sold for laboratory use only, not for human consumption. Always consult a qualified healthcare provider before considering any peptide protocol.